Will Illumina Be a Trillion-Dollar Stock by 2035?
Between its laboratory-ready gene sequencing instruments for research use and its high-throughput equipment for hospitals and diagnostics providers, Illumina (NASDAQ: ILMN) is one of the most essential companies in the entire healthcare sector. If you've ever had your DNA sequenced, I'd bet $20 that your samples passed through one of the company's ubiquitous sequencing machines.
Given that seeing or using its hardware is practically unavoidable in the biopharma sector, it's reasonable to suspect that Illumina could become a giga-cap company in the (distant) future. As long as it maintains its power position in the gene sequencing market, it might even be possible for it to become a trillion-dollar stock. But don't invest your life savings just yet. Illumina will continue to be a juggernaut in the coming decades, but will take quite a while to reach trillion-dollar heights.
Image source: Getty Images.
Source Fool.com
